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Abstract
Background: The incidence of invasive cervical cancer in HIV-positive women is higher than in the general population. 
There is evidence that HIV-positive women do not participate sufficiently in cervical cancer screening in Italy, where 
cervical cancer is more than 10-fold higher in women with AIDS than in the general population. The aim of the present 
study was to evaluate the history of Pap-smear in HIV-positive women in Italy in recent years. We also examined the 
sociodemographic, clinical, and organizational factors associated with adherence to cervical cancer screening.
Methods: A cross-sectional study was conducted between July 2006 and June 2007 in Emilia-Romagna region 
(Northern Italy). All HIV-positive women who received a follow-up visit in one of the 10 regional infectivology units 
were invited to participate. History of Pap-smear, including abnormal smears and subsequent treatment, was 
investigated through a self-administered anonymous questionnaire. The association between lack of Pap-smear in the 
year preceding the interview and selected characteristics was assessed by means of odds ratios (OR) and 95% 
confidence intervals adjusted for study centre and age.
Results: A total of 1,002 HIV-positive women were interviewed. Nine percent reported no history of Pap-smear, and 
39% had no Pap-smear in the year prior to the date of questionnaire (last year). The lack of Pap-smear in the last year 
was significantly associated with age <35 years (OR = 1.4, compared to age ≥45 years), lower education level (OR = 1.3), 
first HIV-positive test in the last 2 years (OR = 1.4), and CD4 count <200 cells/μl (OR = 1.6). Conversely, when women 
were advised by a gynecologist rather than other health workers to undergo screening, it significantly increased 
adherence. Non-significantly higher proportions of lack of Pap-smear in the last year were found in women born in 
Central-Eastern Europe (OR = 1.8) and Africa (OR = 1.3). No difference in history of Pap-smear emerged by mode of HIV-
acquisition or AIDS status.
Three hundred five (34%) women reported a previous abnormal Pap-smear, and of the 178 (58%) referred for 
treatment, 97% complied.
Conclusions: In recent years the self-reported history of Pap-smear in HIV-positive women, in some public clinics in 
Italy, is higher than previously reported, but further efforts are required to make sure cervical cancer screening is 
accessible to all HIV-positive women.
Background
The incidence of invasive cervical cancer in HIV-positive
women is higher than in the general population [1]. This
elevated incidence varies from country to country
depending on study site and characteristics of the popula-
tions under study [2-4]. The weaker association between
HIV-infection and cervical cancer risk in some countries
seems to be explained by competing risks of death (e.g.: in
Africa), or early detection of pre-invasive lesions (e.g.: in
the United States) [5].
Effective screening and early treatment of precancerous
cervical lesions are key factors in preventing the progres-
sion to invasive cervical cancer in both HIV-positive and
-negative women [6]. Recent guidelines recommend that,
following two initial normal Pap-smears at a 6-month
interval, all HIV-positive women should undergo annual
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Page 2 of 6cervical cytologic examination [7]. In addition, it is rec-
ommended that all immunosuppressed women with
atypical squamous cells undergo colposcopy [7].
In the United States, approximately 80% of HIV-posi-
tive women reported a history of Pap-smear in the past
year [8,9]. Low incidence rates of invasive cervical cancer,
similar to those among HIV-negative women, were found
among adequately screened HIV-positive women [10]. In
contrast, there is evidence that HIV-positive women do
not participate sufficiently in cervical cancer screening in
Southern European countries such as Italy and Spain,
where cervical cancer incidence is more than 10-fold
higher in women with AIDS than in general population
[3,5,11,12].
In Italy, one-half of women with invasive cervical can-
cer as the AIDS-defining illness (3% of all women with
AIDS) had their first HIV-positive test ≥10 years before
cancer diagnosis [12]. This long interval suggests a failure
to stop the progression of precancerous lesions through
screening, despite the knowledge of HIV infection.
A large cross-sectional study showed not only a scanty
use of Pap-smear among HIV-positive Italian women, but
also that these women did not know that a Pap-test was
used to prevent cervical cancer [13]. In addition, a survey
conducted among clinicians in 27 Italian HIV centers
showed low compliance with the published guidelines on
gynecologic follow-up of HIV-positive women in Italy
[14].
The aim of the present study was to evaluate the recent
history of Pap-smear in HIV-positive women in Italy fol-
lowed in public HIV clinics. We also examined the socio-
demographic, clinical, and organizational factors
associated with the lack of adherence to screening recom-
mendations.
Methods
Study population
A cross-sectional study was conducted between July 2006
and June 2007 the in Emilia-Romagna Region (Northern
Italy). At end of 2006, this region covered an area of more
than 22.000 km2 (7% of Italy), with a population of 4.2
million inhabitants (7% of Italian population). Approxi-
mately 1,500 HIV-positive women are estimated to live in
the Emilia-Romagna Region [15,16]. All HIV-positive
women who underwent a follow-up visit (recommended
every 6-months) in one of the 10 regional infectivology
units were invited to participate. The study period was
limited to one year in order to reduce the possibility of
duplication.
A total of 1,108 HIV-positive women were invited and
1,002 (90.4%) accepted to participate. Study aims were
explained and written informed consent was obtained
from study women, who subsequently completed a self-
administered anonymous questionnaire. History of Pap-
smear was investigated in detail to assess lifetime screen-
ing, including dates of first and last Pap-smear, and num-
ber of Pap-smears in the three years preceding the
questionnaire. The questionnaire included additional
items on the place where Pap-smear was taken, HPV test-
ing, history of abnormal smears, and treatment of cervi-
cal lesions. Other collected data included
sociodemographic factors (e.g., age, education level, and
country of birth), smoking and reproductive history, sex-
ual habits (e.g., age at first intercourse, lifetime number of
sexual partners, and use of contraceptive methods), and
history of HIV infection (e.g., date of first HIV-positive
test and most probable route of HIV acquisition). In a
separate form, the attending infectivologist reported
information on the course of HIV-infection (e.g.: HIV-
related hospitalization, last CD4 count and HIV RNA val-
ues, AIDS status, and AIDS-defining conditions).
The Ethical Committees of all participating centers
approved the study protocol.
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (CIs)
were used as the measures of association between history
of Pap-smear and women's characteristics, and were esti-
mated using logistic regression models adjusted for study
centre and age [17,18]. Estimates were also calculated
including further adjustment for area of birth, mode of
HIV acquisition, and time since first HIV-positive test.
Results
A total of 1,002 HIV-positive women completed the
questionnaire. The median age was 41 years and the vast
majority of women (87%) fell in the 30-to-49-year age
range. Eighty percent of our study women were born in
Italy and nearly two-thirds reported sexual intercourse as
the route of HIV acquisition. One hundred eighty (18%)
women had a previous AIDS diagnosis and 56% had their
first HIV-positive test 10 or more years prior to the ques-
tionnaire.
Nine percent of women reported no history of Pap-
smear and 305 (34%) had abnormal Pap-smear results
(Figure 1). Women with no history of Pap-smear were
younger and more likely to be born in Central-Eastern
Europe (15%) or Africa (29%) than women reporting pre-
vious Pap-smears (3% and 9%, respectively) (data not
shown). HPV test was reported by only 27% of women
(Figure 1).
Overall, 607 (61%) of the 1,002 HIV-positive women
had a Pap-smear in the year prior to questionnaire (last
year, Table 1). Women younger than 35 years (OR, com-
pared to age ≥45 = 1.4; 95%CI: 1.0-2.0), those with lower
education level (OR = 1.3; 95%CI: 1.0-1.7), those with
recent first HIV-positive test (OR for ≤2 years vs ≥10
years = 1.4; 95%CI: 1.0-2.1), or a CD4 count of <200 cells/
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Page 3 of 6μl (OR compared to ≥500 = 1.6; 95%CI: 1.0-2.5) were
more likely to have no history of Pap-smear in the year
before questionnaire. Non-significantly higher propor-
tions of lack of Pap-smear in the last year were found in
women born in Central-Eastern Europe (OR = 1.8;
95%CI: 0.9-3.6) and Africa (OR = 1.3; 95%CI: 0.8-2.0). No
difference in Pap-smear history emerged by mode of HIV
acquisition, or AIDS status.
Receiving screening advice from a gynecologist rather
than an infectivologist (OR = 0.6; 95%CI: 0.4-0.9) and his-
tory of abnormal Pap-smear (OR = 0.5; 95%CI: 0.3-0.6)
were associated with better screening participation
(Table 1). The multivariate models, including additional
terms for area of birth, mode of HIV acquisition, and time
since first HIV-positive test, did not materially modify
the risk estimates even if associations with age and first
HIV-positive test were not statistically significant (Table
1).
Among the 305 women who reported a previous abnor-
mal Pap-smear, treatment was recommended for 178
(58%); of whom, 173 (97%) complied. Among the 127
(42%) women who were referred for further testing but
not treatment, 84 (66%) underwent all the recommended
follow-up tests.
Among the 178 women to whom treatment was recom-
mended, 145 (81%) reported colposcopy and all follow-up
tests. Conization was the surgical procedure most fre-
quently reported by patients (122, 69%), followed by hys-
terectomy (19, 11%), and cryotherapy (8, 4%).
Discussion
This study was the first attempt to provide estimates of
self-reported Pap-smear history in HIV-positive women
attending infectivology units of a large Italian region. We
found that 91% of women had had at least one Pap-smear
in their lifetime, and 61% reported a Pap-smear in the last
year. These proportions are similar to the ones reported
by the general population of the same age and geographi-
cal area (95% and 47%, respectively) (Carrozzi and Ber-
tozzi, personal communication), and substantially higher
than those reported (43%) in 2001 by a physician-based
Italian survey [14]. Increase in the number of Pap-smears
performed, however, is difficult to evaluate, given the dif-
ferent study designs of previous studies conducted in
Italy [13,14]. The proportion of women who had a Pap-
smear in the last year, however, remains suboptimal with
respect to current guidelines regarding HIV-positive
women (annual Pap-smear recommended to all patients),
and is lower than the estimates (approximately 80%)
reported in the USA [8,9].
Factors associated with lack of recent Pap-smear were
young age (<35 years), recent HIV diagnosis (≤2 years),
and more advanced diseases (CD4 count at last visit <200
cells/μL). Conversely, receiving screening advice from a
gynecologist significantly improved the adherence to
Pap-smear. We found less influence of education level or
country of birth than a previous cross-sectional study
conducted in Rome [13]. As expected, study women
reported a high proportion of previous abnormal Pap-
smears (34%), in agreement with previous reports among
HIV-positive women in Italy [13] and the United States
[8,9].
Overall, our study highlights the difficulties in follow-
ing the recommended protocol of combining routine fol-
low-up of HIV infection with gynecological examination,
which is generally not performed in infectivology units
[5,10]. In addition, patient compliance needs to be
improved [14] and health professionals (e.g., infectious
disease specialists and gynecologists) should thoroughly
inform HIV-positive women (particularly the disadvan-
taged ones) of the importance of Pap-smear to their
health.
The present study has strengths and weaknesses.
Strengths included the high participation among unse-
lected women attending infectivology units. Approxi-
mately 1,500 HIV-positive women are estimated to live in
the Emilia-Romagna Region [15,16] and all women
attending HIV follow-up (recommended every 6 months)
were contacted in a 1-year period. A previous study in
Northern Italy [19] showed that patients infected with
Figure 1 Pap-smear practice and treatment after a positive Pap-
smear in HIV-positive women. Emilia-Romagna Region, Italy, 2006-
2007
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Page 4 of 6Table 1: Odds ratio (OR) and corresponding 95% confidence intervals (CI) for lack of Pap-smear in the last year by selected 
characteristics
Pap-smear in the last year
Yes No OR† (95%CI) OR‡ (95%CI)
n (%) n (%)
Total 607 (60.6) 395 (39.4)
Age at interview (years)
≥45 145 (58.7) 102 (41.3) 1 1
40-44 227 (65.6) 119 (34.4) 0.8 (0.5-1.1) 0.8 (0.5-1.1)
35-39 131 (63.3) 76 (36.7) 0.8 (0.6-1.2) 0.8 (0.6-1.2)
<35 104 (51.5) 98 (48.5) 1.4 (1.0-2.0) 1.2 (0.8-1.8)
Education level
High school/University 255 (63.1) 149 (36.9) 1 1
Middle school/Primary 241 (55.9) 190 (44.1) 1.3 (1.0-1.7) 1.3 (1.0-1.7)
Area of birth
Italy 495 (62.1) 302 (37.9) 1 1
Abroad 112 (54.6) 93 (45.4) 1.2 (0.8-1.7) 1.1 (0.8-1.6)
Central-Eastern Europe§ 17 (42.5) 23 (57.5) 1.8 (0.9-3.6) 1.7 (0.8-3.3)
Africa 56 (53.3) 49 (46.7) 1.3 (0.8-2.0) 1.1 (0.7-1.9)
Other countries 39 (65.0) 21 (35.0) 0.8 (0.5-1.5) 0.9 (0.5-1.5)
Mode of HIV acquisition
Sexual 336 (62.1) 205 (37.9) 1 1
Injecting drug use 164 (61.0) 105 (39.0) 1.2 (0.9-1.6) 1.1 (0.8-1.6)
Other/Unknown 107 (55.7) 85 (44.3) 1.2 (0.8-1.6) 1.1 (0.7-1.5)
Time since first HIV+ test (years)
≥10 357 (63.2) 208 (36.8) 1 1
3-9 169 (62.1) 103 (37.9) 0.9 (0.7-1.3) 0.9 (0.7-1.3)
≤2 78 (48.4) 83 (51.6) 1.4 (1.0-2.1) 1.3 (0.9-2.0)
Previous AIDS diagnosis
No 504 (61.3) 318 (38.7) 1 1
Yes 103 (57.2) 77 (42.8) 1.2 (0.9-1.7) 1.2 (0.9-1.7)
CD4 count at last visit (cells/μl)
≥500 284 (63.5) 163 (36.5) 1 1
200-499 271 (58.8) 190 (41.2) 1.2 (0.9-1.6) 1.2 (0.9-1.5)
<200 45 (51.7) 42 (48.3) 1.6 (1.0-2.5) 1.6 (1.0-2.6)
Screening advice received from
Infectivologist 244 (66.8) 121 (33.2) 1 1
Gynecologist 122 (77.2) 36 (22.8) 0.6 (0.4-0.9) 0.6 (0.4-1.0)
Screening program 61 (59.8) 41 (40.2) 1.4 (0.9-2.2) 1.3 (0.8-2.1)
Do not remember 180 (47.7) 197 (52.3) 2.1 (1.5-2.8) 2.2 (1.6-2.9)
Hospitalized for HIV
No 382 (61.8) 236 (38.2) 1 1
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Page 5 of 6Yes 225 (58.6) 159 (41.4) 1.2 (0.9-1.5) 1.2 (0.9-1.5)
Abnormal Pap-smear#
Never 366 (61.7) 227 (38.3) 1 1
Ever 235 (77.0) 70 (23.0) 0.5 (0.3-0.6) 0.4 (0.3-0.6)
Emilia-Romagna region, Italy, 2006-2007*
* Figures may not add up to totals because of missing values. †Estimates from the logistic regression models adjusted for age and study centre; 
‡Adjusted as † plus terms for area of birth, mode of HIV acquisition, and time since first HIV-positive test. §Included Albania, Bulgaria, Former-
Yugoslavia, Poland, Romania, Hungary, Former-USSR, Czech Republic and Slovakia, Cyprus; #Women reporting no previous Pap-smear were 
excluded
Table 1: Odds ratio (OR) and corresponding 95% confidence intervals (CI) for lack of Pap-smear in the last year by selected 
characteristics (Continued)
HIV through injecting drug use, patients without AIDS the Emilia-Romagna Region can be extended to other
diagnosis, or patients with higher CD4 counts are more
likely to miss medical appointments and discontinue
their follow-up. It is unlikely that HIV-positive women in
the region received their follow-up visits elsewhere, given
the high standard of medical care provided (free of
charge) in Emilia-Romagna in comparison with other
Italian areas. However, the possibility of some socio-
demographic bias in women who did not attend regularly
follow-up cannot be totally ruled out.
The number of self-reported Pap-smears among HIV-
positive women in our study may be an overestimate as
women tend to over-report their participation in cervical
cancer screening in a given timeframe [20]. Confidential-
ity prevented us from linking women's reports with gyne-
cological and cytological records, thus leaving substantial
uncertainty about the actual additional tests and treat-
ments performed. To validate self-reported Pap-smear
use and to follow-up the treatment of HIV-positive
women diagnosed with gynaecological lesions, a new
study is being planned, which will adopt broader confi-
dentiality rules and obtain a written consent to follow-up.
The most important limitation of our survey, however, is
the restriction to HIV-positive women followed by public
clinics in one of the best organized regions of Italy, in
terms of participation and quality of cervical cancer
screening [21,22].
Conclusions
Our study showed that progresses have been made to
screen adequately HIV-positive women in Italy and that
such efforts can also reach the most vulnerable popula-
tions (e.g.: immigrants). The opportunity to prevent cer-
vical cancer in women living with HIV infection should
not be missed; successful implementation of such screen-
ing programs will also teach valuable lessons that could
then be applied to all women [5]. There is, however, still
some scope for improvement, especially in the complete-
ness of treatment and follow-up of HIV-positive women
with an abnormal Pap-smear. Most importantly, much
remains to be done to make sure that the experience of
parts of Italy.
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